FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions concerns medicine and can be used in the patient for treatment or prevention of the infection caused by hepatitis type C virus. That is ensured by administration of VX-950 or its pharmaceutically acceptable salt. Each of inventions characterises certain modes of administration of VX-950 to ensure effective treatment of the disease. The declared methods provide maintenance of minimum plasma concentration of VX-950 for 24 hours, decrease of the ALT level, considerable reduction of the RNA plasma level of hepatitis type C virus and enabled steady virus response.
EFFECT: preparation of the medicine for treatment or prevention in the patient of the infection caused by hepatitis type C virus.
29 cl, 10 ex, 17 dwg
